Archived explainer. For the current picture see today's BIIB page.
BIOGEN INC (BIIB) is down -6.38% in the latest session. Our newswire has captured 14 stories on BIIB across 10 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Biogen Inc (NASDAQ:BIIB) shares fell 6.38% to $195.69 in a volatile session marked by sharp intraday swings. The decline followed a wave of positive news on Alzheimer’s drug diranersen, which triggered early buying but failed to sustain momentum. The stock opened at $208.20 and briefly hit a high of $217.00 before falling to a session low of $192.70, with volume at 0.3 million shares, below its 3-month average.
Biogen announced positive Phase 2 results for diranersen, showing significant reductions in tau biomarkers and cognitive improvements in early Alzheimer’s patients, according to multiple reports from InvestorsHub, MarketChameleon, and StockTitan. The 60 mg dose slowed decline by 42% on the ADAS-Cog13 and 50% on the MMSE, though the study missed its dose-response endpoint. These findings were presented at the Alzheimer’s Association International Conference (AAIC) and were widely covered in the last 36 hours.
In addition, the FDA approved a subcutaneous version of Biogen’s Alzheimer’s drug Leqembi for at-home use, reported by PR Newswire and Seeking Alpha. This development was initially met with optimism, with Stocktwits News noting a 5% jump in BIIB stock and analysts raising price targets. However, the market’s reaction to the mixed signals from the diranersen trial and the broader context of Alzheimer’s drug competition may have contributed to the subsequent sell-off.
The stock has declined 4.9% over the last eight sessions, from $213.18 to $202.65. Intraday volatility was pronounced, with a high of $217.00 at 9:15 AM ET and a low of $192.70 at 9:45 AM ET. Trading volume remained subdued at 0.3 million shares, or 0.2 times the 3-month daily average. The 52-week range is $121.05 to $219.72, and the stock is currently trading below its 52-week high. Recent social chatter on X showed a 70/100 sentiment score over the past seven days, with two posts in 24 hours.
Biogen does not have an upcoming earnings date in the provided data. Investors should monitor the breadth of coverage and sentiment around the diranersen Phase 3 trial plans and the long-term implications of the Leqembi at-home approval. The stock’s performance may also be influenced by broader Alzheimer’s drug developments and regulatory updates in the sector.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Biogen (NASDAQ:BIIB) gained after positive Phase 2 data for Alzheimer's drug diranersen showed significant reductions in tau biomarkers and encouraging cognitive outcomes, supporting plans to begin Phase 3 development.
Biogen’s investigational tau-targeted therapy, diranersen, delivered meaningful clinical efficacy and significant biomarker improvements in early Alzheimer's disease, according to new Phase 2 CELIA study results presented at the AAIC 2026. While the highest dose did not amplify clinical benefit, the therapy demonstrated a favorable safety profile and strong patient retention, creating momentum for a Phase 3 trial.
At 60 mg, diranersen slowed decline 42% on ADAS-Cog13 and 50% on MMSE; Biogen plans Phase 3, though CELIA missed its dose-response endpoint.
Clinical outcomes : Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of...
Initiation of treatment with subcutaneous administration opens the door to fully at-home dosing, similar to injectable diabetes and GLP-1 weight loss therapies NEW YORK, July 13, 2026 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved a weekly subcutaneous starting...
FDA approves Biogen/Eisai’s at-home subcutaneous Leqembi for Alzheimer’s, Read more here.
The decision marks a major shift in how patients can begin therapy for early Alzheimer’s disease.
More on BIIB: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BIIB move explainers: 2026-07-14 · 2026-07-13